“Open innovation and R&D investment to create a new new pharmaceutical”

Shinshin Pharm announced on the 5th that it held a kick-off ceremony at the Magok R&D Center on the 4th, pledged to take a leap forward as a global healthcare company, and started working for the new year.

This opening ceremony is the first event held at the Magok R&D Center, which was relocated in July 2020. The event was held non-face-to-face through in-house broadcasting to comply with the social distancing strengthened by the rapid increase in confirmed cases of the new coronavirus infection (Corona 19), and President Lee Byung-ki’s New Year’s Address was also delivered to employees through the broadcast.

President Lee Byung-ki emphasized in his New Year’s address, “Everyone is in a difficult situation because Corona 19 has not ended, but as Shinshin Pharmaceutical has done so far, if employees become one, the crisis will be overcome.”

In addition, “in 2021, we will expand the pipeline through active open innovation, and accelerate the development of patch-type specialty drugs that take advantage of Shinshin Pharmaceutical’s unique strengths.” It is planned.”

“Starting with the biomaterial product developed in conjunction with Phicoil Biotech Korea in February, various new products are planned to be launched, such as the expansion of the lineup of the representative brand Shin Shin Pas Alex.” We will work together as one and write down the history of new Shinshin Pharmaceutical as a global healthcare company.”

Lastly, President Lee Byung-ki cheered the executives and employees by saying, “I hope that we will be able to share the joy by ending a rewarding year with the executives and employees at this meeting one year later.”

–